Additionally, efforts towards the definition of a more standardized and comprehensive approach for the detection of PD-L1 on both tumor cells and immune cells should be a priority for the scientific community, in order to provide the highest possible benefit from immune-checkpoint inhibitors of the PD1/PD-L1 axis to the broadest possible patients population. Here, CD274 is linked to neoplasm.